Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX AMZN BIIB IBB TSLA WYNN ALXN GMCR AMGN COST TRIP WDC VRTX BEAV QCOR AAPL SNDK GILD
Nyse: PXD V ACT IVV IBM GS SPG AGN LMT LNKD PRGO FDX TWC XEC MMM CVX BA NOC TMO
New Highs: SHW IVV SPG LMT XEC PII APD FLT NOC GD NSC SIAL UNP HES APH AAPL AMT PEP MCO AON

The Hot Industries

Business Services 2
Aerospace/Defense Products & Services 2
Railroads 2

The Hot Sectors

Basic Materials 4
Services 4
Consumer Goods 3

ARIA Stock Chart


ARIA
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

307
Monthly

Website:

http://www.ariad.com

ARIA Ariad Pharmaceuticals Inc.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

favicon

Stock Market Today: Biotech, Social Media Stocks Slide Following Yellen's Remarks

15 Jul 2014, 8:06 amNEW YORK (TheStreet) -- Major U.S. stock markets tumbled Tuesday following Federal Reserve Chair Janet Yellen's prepared remarks to the Senate Banking Committee that some sectors of the markets, notably biotech and social media, appear overvalued.  The iShares Nasdaq Biotechnology Index ETF  slid 2.6% on the remarks, as MannKind dropped 1.7%, Geron moved 5% lower, and Ariad Pharmaceuticals  was ...
favicon

Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape

7 Jul 2014, 7:58 amWhy A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
favicon

Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock

7 Jul 2014, 5:42 amWhy A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock
favicon

Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session

3 Jul 2014, 6:16 amAlcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
favicon

Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session

3 Jul 2014, 5:03 amZogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
favicon

Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6%

1 Jul 2014, 4:54 amAuxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
favicon

Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session

26 Jun 2014, 5:00 amHeron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
favicon

ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019

24 Jun 2014, 5:21 pmCAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the ...
favicon

Ohr Pharmaceutical (OHRP) Soars: Stock Adds 16.9% in Session

24 Jun 2014, 4:59 amOhr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise by almost 17% on the day.
favicon

ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 2019

23 Jun 2014, 2:57 pmCAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ...